News & Trends

• 042026-06

  Latest clinical trial data for Salubris' anticancer new drug JK06 presented at ASCO demonstrate favorable safety and efficacy in patients with advanced relapsed/refractory solid tumors.

• 222026-05

  Shenzhen Salubris Pharmaceuticals Receives Acceptance of Clinical Trial Application for Innovative siRNA Drug SAL0195 in Lipid-Related Diseases

• 172026-05

  Salubris’innovative biologic Xinfutai Plus® approved as the first onceweekly teriparatide formulation in China for the treatment of osteoporosis

• 302026-04

  Clinical trial application for Salubris’cyclic peptide drug SAL0167 accepted for the treatment of hyperlipidemia

• 212026-04

  The latest clinical trial data for Salubris' novel anticancer drug, JK06, presented at the AACR, demonstrated favorable safety and efficacy profiles in patients with non-small cell lung cancer and breast cancer

• 022026-04

  Salubris siRNA New Drug SAL0132 Releases Phase I Clinical Data: Single Dose Lowers AGT by Over 90%, Demonstrating Potential for Ultra-Long-Acting Antihypertensive Effect